Clinical Trials Using PI3K-beta Inhibitor GSK2636771
Clinical trials are research studies that involve people. The clinical trials on this list are studying PI3K-beta Inhibitor GSK2636771. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Location: 1172 locations
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Participants with Stage III-IV Cancer or Metastatic Melanoma and PTEN Loss
This phase I / II trial studies the side effects and best dose of PI3K-beta inhibitor GSK2636771 when given together with pembrolizumab and to see how well they work in treating participants with stage III-IV cancer or melanoma that has spread to other places in the body and PTEN loss. PI3K-beta inhibitor GSK2636771 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving PI3K-beta inhibitor GSK2636771 and pembrolizumab may work better in treating participants with cancer or melanoma.
Location: M D Anderson Cancer Center, Houston, Texas